Loading
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$2.025
−$0.025 · -1.22%
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.
Latest quote
$2.025
−$0.025 · -1.22%
After-hours
$2.025
$0.00 · 0.00%
Oct 9, 4:04 PM ET
Regular session · ET · Market data may be delayed.
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.
Day range
Current $2.025
52-week range
Current $2.025
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
59
Fair Value
Sentiment
52
Mixed
Risk
53
Elevated Risk
Momentum
34
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.
Day range
Current $2.025
52-week range
Current $2.025
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 57.57M USD | 66.38M USD | 65.18M USD | 107.4M USD | 96.67M USD |
| Cost of goods sold | 20.75M USD | 20.55M USD | 16.13M USD | 40.77M USD | 46.39M USD |
| Gross profit | 36.82M USD | 45.83M USD | 49.05M USD | 66.63M USD | 50.28M USD |
| Research and development | — | 1.33M USD | 2.77M USD | 4.1M USD | 12.66M USD |
| Selling, general, and administrative | 42.64M USD | 38.29M USD | 42.04M USD | 70.08M USD | 69.88M USD |
| Operating expenses | 45.13M USD | 53.66M USD | 50.65M USD | 83.7M USD | 160.19M USD |
| Interest income | — | — | — | — | 14K USD |
| Interest expense | −1.9M USD | 3.7M USD | 4.79M USD | 4.96M USD | 147.5M USD |
| Depreciation and amortization | 3.93M USD | 5.38M USD | 6.73M USD | 8.82M USD | 10.15M USD |
| Operating income | −8.32M USD | −7.83M USD | −1.59M USD | −17.07M USD | −109.91M USD |
| Net income | −14.25M USD | −13.56M USD | −15.84M USD | −17.05M USD | −108.78M USD |
Company facts updated Oct 9, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jan 6, 2023 | 1:20 | — | — |
Stock split | Dec 9, 2020 | 1:10 | — | — |
Stock split | Aug 13, 2018 | 1:20 | — | — |
Stock split | Aug 29, 2017 | 1:20 | — | — |
Stock split | Oct 28, 2016 | 1:12 | — | — |
Stock split | Jul 1, 2016 | 1:12 | — | — |
Effective Jan 6, 2023
1:20
Effective Dec 9, 2020
1:10
Effective Aug 13, 2018
1:20
Effective Aug 29, 2017
1:20
Effective Oct 28, 2016
1:12
Effective Jul 1, 2016
1:12
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
